Advanced Solid Tumors
Conditions
Brief summary
The goal of this clinical trial is to assess the safety and tolerability of AT1019 when used in combination with SBRT and PD-1 inhibitor, and determine the maximum tolerated dose (MTD) of AT1019 in the combination therapy of SBRT and PD-1 inhibitor in patients with advanced solid tumors. The main questions it aims to answer are: Is the combination of AT1019, SBRT and PD-1 inhibitor safe and well-tolerated in patients with advanced solid tumors? What is the maximum tolerated dose (MTD) of AT1019 when combined with SBRT and PD-1 targeted immunotherapy? Participants will: * First receive PD-1 inhibitor treatment as scheduled. * Undergo SBRT, which will be given in 3 to 5 fractions, with each fraction ranging from 6Gy to 18Gy, and the treatment will be administered once a week. * Receive intratumoral injection of AT1019 within 1 to 2 days after each SBRT session. * Undergo imaging examinations every 6 weeks (with a tolerance of ±1 week) to evaluate the treatment effect.
Interventions
DRUGAT1019
1. First receive PD-1 inhibitor treatment. 2. Undergo SBRT, which will be given in 3 to 5 fractions, with each fraction ranging from 6Gy to 18Gy, and the treatment will be administered once a week. 3. Receive intratumoral injection of AT1019 within 1 to 2 days after each SBRT session.
Sponsors
The Affiliated Hospital of Xuzhou Medical University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female patients aged ≥ 18 years. 2. Signed the informed consent form and have the psychological capacity to understand it. 3. Patients with advanced solid malignant tumors (such as non-small cell lung cancer, renal cell carcinoma, head and neck cancer, cervical cancer, and urothelial carcinoma) who are receiving immunotherapy and planned to undergo SBRT. Patients are eligible if they achieved at least stable disease during previous immunotherapy. 4. Patients' disease must be evaluated according to RECIST v.1.1. 5. Presence of metastatic lesions amenable to radiation therapy. 6. Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 1. 7. No evidence of clinically significant conduction abnormalities or active ischemia on electrocardiogram (ECG), as judged by the investigator. 8. Acceptable organ and bone marrow function as demonstrated by the following criteria: (1) Absolute neutrophil count \> 1500 cells/μL; (2) Platelet count \> 50,000 cells/μL; (3) Total bilirubin ≤ 1.5 times the upper limit of normal (ULN); (4) Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 2.5 times the ULN; if hepatic metastasis exists, AST/ALT \< 5 times the ULN; (5) Serum creatinine \< 1.5 mg/dL and creatinine clearance ≥ 50 mL/min as calculated by the Cockcroft-Gault formula; (6) Prothrombin time (PT)/partial thromboplastin time (PTT) ≤ 1.5 times the ULN. 9\. Females of childbearing potential (defined as those who have experienced menarche and have not undergone successful surgical sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or are not postmenopausal (defined as at least 12 months of amenorrhea with appropriate clinical documentation, such as age \> 45 years)) must undergo a serum pregnancy test prior to the first administration of study treatment and confirm a negative result. 10\. Male and female patients of childbearing potential must agree to use two effective contraceptive methods throughout the study period.
Exclusion criteria
1. Previous therapeutic radiotherapy to the same lesion. 2. Failure to recover to grade 1 or lower from clinically significant adverse events related to prior anticancer therapy, as judged by the investigator. 3. Previous grade 4 toxicity attributed to immunotherapy. 4. Known untreated brain metastases or treated but unstabilized brain metastases (central nervous system lesions shown on scan to be non-progressive and not requiring corticosteroid use) ≥ 4 weeks prior to enrollment. 5. QT/QTc interval prolongation (QTc interval \> 470 milliseconds). 6. Uncontrolled intercurrent illnesses (including but not limited to ongoing or active infections, symptomatic congestive heart failure, unstable angina, arrhythmias, or psychiatric/social conditions) that, in the investigator's judgment, would limit the patient's compliance with study requirements. 7. Pregnant or lactating women. 8. The Sponsor reserves the right to exclude any patient based on pre-study medical history, physical examination findings, clinical laboratory results, prior medications, or other enrollment criteria.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose-limiting toxicity (DLT) | Four weeks after the end of the combination therapy. | Determine the DLT of AT1019 in the combination therapy of SBRT and PD-1 inhibitor. |
| Maximum tolerated dose (MTD) | Four weeks after the end of the combination therapy. | Determine the MTD of AT1019 in the combination therapy of SBRT and PD-1 inhibitor. |
| Adverse event (AE) | From the first dose to 12 months after the last dose. | Rates and severity of AEs assessed by CTCAE v5.0 criterion. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Abscopal effect rate | 3 months after the end of the combination therapy. | The proportion of patients with an abscopal response assessed by RECIST v1.1 criterion. |
| Progress-free survival (PFS) | 5 years after the end of the combination therapy. | To evaluate PFS of AT1019 in combination with SBRT and PD-1 inhibitor. PFS was defined from date of recruit to date of first documentation of progression or death due to any cause. |
| Objective response rate (ORR) | Six weeks (with a tolerance of ±1 week) after the end of the combination therapy. | To evaluate ORR of AT1019 in combination with SBRT and PD-1 inhibitor based on RECIST v1.1 criterion. |
| Disease control rate (DCR) | Six weeks (with a tolerance of ±1 week) after the end of the combination therapy. | To evaluate DCR of AT1019 in combination with SBRT and PD-1 inhibitor based on RECIST v1.1 criterion. |
Countries
China
Contacts
Primary ContactHui Qiu, M.D., Ph.D.
Outcome results
None listed